Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217104 | 0.90 | VCAM1 (0.55) | ALDH1A1VCAM1MAPTKDM4EHPGD | |
| SCHEMBL29930566 | 0.86 | VCAM1 (0.51) | ALDH1A1VCAM1MAPTKDM4EHPGD | |
| SCHEMBL29407123 | 0.86 | VCAM1 (0.51) | ALDH1A1VCAM1MAPTKDM4EHPGD | |
| SCHEMBL5217118 | 0.86 | VCAM1 (0.51) | ALDH1A1VCAM1MAPTKDM4EHPGD | |
| SCHEMBL28690833 | 0.86 | VCAM1 (0.51) | ALDH1A1VCAM1MAPTKDM4EHPGD | |
| SCHEMBL12774975 | 0.84 | VCAM1 (0.50) | ALDH1A1VCAM1MAPTKDM4EHPGD | |
| SCHEMBL636992 | 0.84 | VCAM1 (0.50) | ALDH1A1VCAM1MAPTKDM4EHPGD | |
| SCHEMBL20839509 | 0.84 | TPMT (0.54) | ALDH1A1VCAM1MAPTKDM4EHPGD | |
| SCHEMBL30153000 | 0.84 | MEN1 (0.51) | ALDH1A1VCAM1MAPTKDM4EHPGD | |
| SCHEMBL443827 | 0.84 | MEN1 (0.51) | ALDH1A1VCAM1MAPTKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692095-A1 | SALT CRYSTAL FORM OF QUATERNARY FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-20250171464-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-12275745-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240400582-A1 | FOUR-MEMBERED FUSED RING COMPOUND AND PREPARATION METHOD AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| WO-2024199447-A1 | SALT CRYSTAL FORM OF QUATERNARY FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏豪森药业集团有限公司 | 2024-10-03 | — | — | WO | disclosed |
| EP-4436969-A2 | BICYCLIC THERAPEUTIC COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-4410779-A1 | FOUR-MEMBERED FUSED RING COMPOUND AND PREPARATION METHOD AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2024-08-07 | — | — | EP | disclosed |
| CN-118451077-A | Bicyclic therapeutic compounds and methods for treatment of cancer | 基因泰克公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-118139849-A | Quaternary condensed ring compound and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| WO-2011058473-A1 | N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110111046-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC | 2011-05-12 | — | — | US | disclosed |
| WO-2010111058-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010111058-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010034796-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| US-20060229302-A1 | Tricyclic indole derivatives and their use in the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-10-12 | — | — | US | disclosed |
| CN-1809573-A | Tricyclic indole derivatives and their use in the treatment of alzheimer's disease | GLAXO GROUP LTD (GB) | 2006-07-26 | — | — | CN | disclosed |
| WO-2006040148-A1 | TRICYCLIC INDOLE DERIVATIVES FOR USE IN THE TREATMENT OF ALZHEIMER’S DISEASE | GLAXO GROUP LIMITED (GB) | 2006-04-20 | — | — | WO | disclosed |
| EP-1620438-A1 | TRICYCLIC INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004094430-A1 | TRICYCLIC INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER’S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229302-A1 | Tricyclic indole derivatives and their use in the treatment of alzheimer's disease | BACE2, BACE1, PSEN2 | ALDH1A1 3673/4885CYP3A4 1874/4885VCAM1 3456/4885 |
| US-20240400582-A1 | FOUR-MEMBERED FUSED RING COMPOUND AND PREPARATION METHOD AND USE THEREOF | ABL1, ABL2, BCR | ALDH1A1 2519/4885CYP3A4 1162/4885VCAM1 3112/4885 |
| US-20250171464-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | ALDH1A1 829/4885CYP3A4 2755/4885VCAM1 773/4885 |
| US-20110111046-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | ALDH1A1 164/4885CYP3A4 1017/4885VCAM1 4224/4885 |
| US-20230203062-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | ALDH1A1 829/4885CYP3A4 2755/4885VCAM1 773/4885 |
| US-12275745-B2 | Therapeutic compounds and methods of use | VHL, TP53, MCL1 | ALDH1A1 829/4885CYP3A4 2755/4885VCAM1 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.